Stay updated on Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoChange DetectedNew data points were added to the study record, including several key dates (2026-01-02, 2023-08-04, 2027-09-01, 2025-12-30) and a Last Update Posted (Estimated) label. Older sponsor details and past update entries (e.g., Nancy Chan, MD, Big Ten Cancer Research Consortium) were removed.SummaryDifference0.8%

- Check17 days agoNo Change Detected
- Check24 days agoChange Detected- Added a new Locations section listing Michigan, Nebraska, New Jersey, New York, and Wisconsin. Removed the separate Michigan, Nebraska, New Jersey, New York, and Wisconsin location blocks.SummaryDifference0.7%

- Check38 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2; this appears to be a minor backend or formatting change with no edits to study details, eligibility, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check52 days agoChange DetectedRevision updated from v3.2.0 to v3.3.1 on the page.SummaryDifference0.1%

- Check60 days agoChange DetectedThe funding status warning banner was removed from the page, removing the notice about potential information delays due to government funding. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check74 days agoChange DetectedStudy Details page appears unchanged; no additions or deletions detected.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.